Level D· Scientific groundwork from lab and animal studiesNarrative ReviewPubMed

Bone Tissue Regeneration - Application of Mesenchymal Stem Cells and Cellular and Molecular Mechanisms.

Zhang J., Chen J.

Narrative Review on Hair & Scalp, published in Curr Stem Cell Res Ther (2017) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Narrative Review
Journal
Curr Stem Cell Res Ther (2017)
Country
United Arab Emirates
Reported sample size
—
Source database
PubMed
PMID
27658728
DOI
10.2174/1574888X11666160921121555

Abstract (original English)

The regeneration of damaged bone tissues to a pre-disease state has been a major goal for both clinicians and researchers worldwide. However, critical-sized bone defects which are unable to heal completely are a major clinical concern because effective, evidencebased regenerative therapy is still missing. Bone tissue engineering, aiming at providing novel and effective materials to promote bone regeneration, has been considered as a promising alternative to the traditional use of autografts, allografts and xenografts based on the fact that engineered bone tissue has limitless supply and has no disease transmission. Mesenchymal stem cells (MSCs) can be derived from various adult tissues such as adipose tissues, dental follicles of wisdom teeth, bone marrow, dental pulp, gingiva, etc., which do not raise any ethical concerns. Furthermore, the application of MSCs in bone tissue engineering has moved to the preclinical stage, and an ex vivo cell manufacturing procedure for obtaining high quality, bioactive MSCs from human bone marrow has been approved by the US Food and Drug Administration (FDA). In this review, we summarized the cell sources and biological characteristics of MSCs, discussed the in vivo functions of MSCs during bone regeneration, and briefly introduced the strategies for the application of MSCs in bone tissue engineering. Further research efforts are still needed t

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsBone RegenerationHumansMesenchymal Stem CellsOsteoblastsOsteoclastsTissue Engineering

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research